LeaderPortfolio
Troendle
August Troendle
Rank #1184
UNITED STATESHealthcarePharmaceutical services

August Troendle

Net Worth
$3.584B
-0.17% (24h)
August Troendle, a medical doctor, is the CEO and Chairman of Medpace, a leading clinical research organization (CRO). His estimated net worth is $3.5 billion as of March 25, 2026. Troendle's wealth stems from his founding of Medpace in 1992, which provides clinical trial services to pharmaceutical and biotechnology companies. His career includes experience as a Medical Review Officer at the FDA and leadership roles at Sandoz (Novartis). Troendle's strategic vision has propelled Medpace to global recognition.

How to read August Troendle's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For August Troendle, we anchor the narrative to Pharmaceutical services and Pharmaceutical services, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $3.584B alongside global rank #1184, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (UNITED STATES) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life

August Troendle, born January 1, 1956, is a medical doctor who embarked on a career path that blended regulatory oversight, pharmaceutical development, and entrepreneurship. He earned his Medical Degree from the University of Maryland, School of Medicine. His early experience included serving as a Medical Review Officer in the Division of Metabolic and Endocrine Drug Products at the FDA.

Rise to Success

Troendle's career included a stint at Sandoz (Novartis), where he was responsible for the clinical development of lipid-altering agents. Recognizing the need for high-quality clinical research services, he founded Medpace in Cincinnati, Ohio, in 1992. He served as President through July 31, 2021.

Key Business Strategies

Troendle's leadership has been key to Medpace's growth. Medpace offers comprehensive solutions for drug and medical device testing. He owns nearly 20% of Medpace stock. Medpace's 2024 revenues were approximately $2.11 billion.

Philanthropy

August Troendle is recognized for his philanthropy, supporting healthcare initiatives and research endeavors.

Career Timeline

1992

Founder of Medpace

Founded Medpace in Cincinnati, Ohio

1987-1992

Manager

Worked at Sandoz (Novartis), responsible for the clinical development of lipid altering agents

1986-1987

Medical Review Officer

Worked in the Division of Metabolic and Endocrine Drug Products at the FDA

Philanthropic Impact

Healthcare$XB

Healthcare Initiatives and Research

Supports healthcare initiatives and research endeavors in the Cincinnati community and beyond.

Key Business Ventures & Holdings

CompanyStakeValue
Medpace Holdings Inc (MEDP)18.95%$2.43M

Net Worth History

In-Depth Analysis

Early Life

August Troendle, born January 1, 1956, is a medical doctor who embarked on a career path that blended regulatory oversight, pharmaceutical development, and entrepreneurship. He earned his Medical Degree from the University of Maryland, School of Medicine. His early experience included serving as a Medical Review Officer in the Division of Metabolic and Endocrine Drug Products at the FDA.

Rise to Success

Troendle's career included a stint at Sandoz (Novartis), where he was responsible for the clinical development of lipid-altering agents. Recognizing the need for high-quality clinical research services, he founded Medpace in Cincinnati, Ohio, in 1992. He served as President through July 31, 2021.

Key Business Strategies

Troendle's leadership has been key to Medpace's growth. Medpace offers comprehensive solutions for drug and medical device testing. He owns nearly 20% of Medpace stock. Medpace's 2024 revenues were approximately $2.11 billion.

Philanthropy

August Troendle is recognized for his philanthropy, supporting healthcare initiatives and research endeavors.

Data Sources & Methodology

Figures for August Troendle are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.